The role of interventional radiology in the treatment of epiphora

Francesca Patella¹, Silvia Panella¹, Stefania Zannoni¹, Maria Laura Jannone¹, Filippo Pesapane¹, Salvatore Alessio Angileri¹,², Sara Sbaraini¹, Anna Maria Ierardi¹, Simone Soldi², Giuseppe Franceschelli², Gianpaolo Carrafiello²

¹Postgraduation School of Radiodiagnostic of Milan, Milan, Italy; ²Diagnostic and Interventional Radiology Service, San Paolo Hospital, Milan, Italy

Contributions: (I) Conception and design: F Patella; (II) Administrative support: G Carrafiello; (III) Provision of study materials or patients: G Carrafiello; (IV) Collection and assembly of data: F Patella; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Francesca Patella. Postgraduation School of Radiodiagnostic of Milan, Milan, Italy. Email: battellina@gmail.com.

Abstract: Epiphora is a relatively common ophthalmologic affection representing almost 5% of clinical consultations in ophthalmology and it consists in the complete or partial obstruction of nasolacrimal duct, leading to insufficient drainage of tears. The traditional treatment is represented by surgery namely, external dacryocystorhinostomy (DCR). Despite the high success rate DCR has many disadvantages and limitations since it requires general anesthesia, it may arise in a permanent facial scar and it is often affected by the reobstruction of the anastomotic tract by fibrotic scars and osteogenic activity. Fluoroscopically guided interventional procedures are a therapeutic alternative to surgery for lacrimal duct system obstructions that can consist either in balloon dacryocystoplasty or in nasolacrimal stent placement. In both cases, a pre-operative imaging characterization of the occlusion is needed for a correct treatment planning. In this review, we propose to highlight the role of interventional radiology in the treatment of epiphora and the role of computed tomography dacryocystography (CTD) in depiction and the pre-interventional planning.

Keywords: Computed tomography; interventional radiology; fluoroscopy; epiphora; dacryocystography; dacryocystoplasty; lacrimal duct

Submitted Sep 07, 2017. Accepted for publication Sep 18, 2017.
doi: 10.21037/gs.2017.09.16

View this article at: http://dx.doi.org/10.21037/gs.2017.09.16

Introduction

The lacrimal drainage system (LDS) serves as a conduit for tear flow from the external eye to the nasal cavity. It consists of superior and inferior punctum and canaliculi, common canaliculus, lacrimal sac and nasolacrimal duct (1). The nasolacrimal duct extends from the inferior portion of the lacrimal sac through the bony lacrimal canal and opens into the inferior meatus of the nasal cavity (1,2).

Nasolacrimal duct obstruction (NLDO) is the complete or partial obstruction of nasolacrimal duct that leads to insufficient drainage of tears, called epiphora (3,4). Excessive tearing is the most common symptom of patients with NLDO, followed by acute or chronic infection (3-5).

NLDO could be either congenital or acquired (related to trauma, inflammatory disease, dacyroliths, neoplasm) (3,4,6). However, the most common cause of NLDO in adults is idiopathic inflammatory obstruction of the nasolacrimal duct, that according to clinic-pathologic studies maybe induced by the compression of the lumen by inflammatory infiltrates and edema, as the possible result of an autoimmune disease or an unidentified infection (7).

This condition affects women twice as frequently as men and peaks in the elderly age (3,4,6). It is a relatively common ophthalmologic affection representing less than 5% of clinical consultations in ophthalmology (3,6).

Surgery constitutes the usual treatment of LDS obstructions below the common canaliculus, namely, external dacryocystorhinostomy (DCR) (6). This is an invasice surgical procedure requiring skin incision and osteotomy to create an anastomosis between the sac and the nasal mucosa to bypass the obstruction. Despite the
high success rate (79–99%), DCR has many disadvantages and limitations (8,9). It requires general anesthesia and it may arise in a permanent facial scar. In addition, the reobstruction of the anastomotic tract by fibrotic scars and osteogenic activity, is the major long-term drawback (6,9).

Described for the first time in 1978 (10), fluoroscopically guided interventional procedures are a therapeutic alternative to surgery for LDS obstructions. They are generally performed by the interventional radiologist and include two different techniques: the balloon dacryocystoplasty or the nasolacrimal stent placement (6).

In both cases, a pre-operative characterization of the occlusion is needed for a correct treatment planning (11). Widely employed in clinical practice, computed tomography dacryocystography (CTD) represents one the most useful radiological option for the depiction of NLDO, enabling the assessment of the site and the severity of the stenosis (11).

In this paper, we aim to report the contribution either of diagnostic and interventional radiological approaches in non-surgical therapy of epiphora.

Methods

Using the terms “epiphora” or “nasolacrimal duct obstructions” and “interventional radiology” or “fluoroscopy” and “dacryocystoplasty” and “nasolacrimal stent placement” and “computed tomography dacryocystography” contained in title and/or abstract and/or keywords, a comprehensive literature review was conducted through Medline, Scopus and Google Scholar (01/01/1990–01/07/2017) databases. Additional from authors’ bibliographies were hand searched.

CTD

Imaging of the LSD is required for the preoperative assessment of epiphora.

Various imaging modalities, including conventional fluoroscopic dacryocystography, nuclear scintigraphy, computed tomography and magnetic resonance imaging (MRI) are available (12), but CTD is certainly one of the most utilized (11,13–16).

Combining CT with dacryocystography, CTD is able to enhance the relationship between the nasolacrimal drainage system and the surrounding soft tissue and bony structures, defining the lacrimal system anatomy, assessing the level and the severity of the stenosis and facilitating preoperative planning (11,15,17).

CTD technique consists of LDS opacification by administration of an iodinate contrast medium by cannulation or direct instillation in the conjunctival cul de sac (18). Cannulation of the lacrimal canaliculi (typically the inferior) should be preceded by irrigation and compression of the lacrimal sac to flush out retained secretions within the LDS, which may lead to interpretive difficulties and misdiagnosis (16,18); then the injection of 0.5–1 mL of contrast medium can be performed through a lacrimal cannula, instilling one or two drops per minute, per eye, for 5 minutes (18).

Images are acquired immediately after contrast administration; patient is scanned in a supine position for axial imaging and then the acquired data are reformatted into 3D and 2D coronal and parasagittal planes along the major axis of the lacrimal drainage apparatus (18).

In a patent system, the contrast medium is supposed to immediately drain from the lacrimal sac into the nose. Thus, a delayed appearance of contrast medium in the nasal cavities can be interpreted as a partial obstruction; while its complete absence associated to its retention in the lacrimal sac should be referred to a complete occlusion of the nasolacrimal duct (11-16,18) (Figures 1,2).

Interestingly, it should be noticed that there is not a strict correlation between the radiological and the clinical findings. Indeed, the lacrimal production decreases with age, so that an occlusion of the LDS can be even depicted in completely asymptomatic patients (19).

The main advantages of CTD over the other modalities, especially over MRI dacryocystography, are wide availability, lower costs, short scanning times, high reproducibility and most of all its ability to provide a precise definition of bone morphology, even showing smaller drainage structures (12). However, since any radiation dose cannot be considered completely safe, other techniques that do not involve administration of ionizing radiation (i.e., MRI dacryocystography) could be advisable in younger patients (12).

Furthermore, CTD should be avoided in patients with allergic diathesis to iodinate contrast media (12,16).

Techniques

Balloon dacryocystoplasty

Introduced by Becker and Berry in 1989 (20), the balloon dacryocystoplasty is an interventional radiological procedure
consisting in the dilatation of a NLDO with the employ of a dedicated balloon catheter, able to apply a radial force on the thickened duct wall (21-23).

After a preliminary digital subtraction dacryocystography (DSD) to confirm the CTD reports, a 20 gauge soft plastic arterial sheath is introduced over a flexible tip metallic guidewire through the superior canaliculus into the LDS and then advanced to the level of the stenosis, where the probe is gently manipulated to cross the obstruction (22). Some authors suggest the use of the plastic sheath for

Figure 1 Computed tomographic dacryocystography demonstrating the lacrimal drainage system (axial and coronal scan), showing contrast in the nasolacrimal duct in the patent right side with opacification of the ipsilateral rhinopharynx, and absence of contrast in the distal left nasolacrimal duct.

Figure 2 Coronal CT-DCG and 3D reconstruction. The CT-DCG shows obstruction of the right lacrimal pathway after the lacrimal sac. On the left side a diverticular retroflection of 6 mm is visible at the level of the proximal nasolacrimal duct.
the negotiation of the stenosis in order to avoid potential damages of the lacrimal duct walls, induced by the relatively stiff part of the guidewire (24). Once the obstruction is crossed, a 0.016 in steerable guidewire is advanced through the sheath into the inferior nasal meatus till the nare (22,24). This part of the intervention can be challenging and may require the employ of specially designed hooks or hemostat tweezers to catch the guidewire. However, the use of these instruments is controversial, since it increases the risk of parietal damages (6).

Thus, under fluoroscopic monitoring in lateral projection, an angioplasty balloon catheter with a 3-French shaft, 2–4 mm in diameter and 2 cm in length, is passed over the guidewire to the site of the stenosis (6,24). The introduction of the balloon can be performed either through an antegrade (from the canaliculus) or a retrograde (from the nasal cavities) approach (25,26).

When the balloon is right positioned, it can be inflated at 5 atm pressure with a water-iodinate contrast medium solution. Effective dilatations are supposed to last for 30 s–5 min, according to the severity of the obstruction (6). The results of the procedure must be checked with a final DSD to verify the patency of the treated duct lumen (22).

The choice of balloon dacryocystoplasty for treatment of epiphora has some major advantages over surgery. Indeed, the procedure does not require hospitalization as it can be performed under topical anesthesia and most of the side effects can be prevented by the prophylactic administration of oral or topical antibiotics and steroid eye drops for 1 week (6). Complications are generally negligible such as temporary mild pain during the intervention or circumscribed bleeding from the nasal cavity or the lacrimal punctum (6).

Another interesting aspect of balloon dacryocystoplasty is that it does not preclude a further surgical intervention (6).

However, the effectiveness of balloon dacryocystoplasty seems to be strictly related to patient selection. Absolute contraindications include LDS neoplasias, acute infective dacryocystitis risking to involve the surrounding tissues and structural deformations of the bony lacrimal canal (20,21,27). Furthermore, balloon dacryocystoplasty success rate seems to be influenced by the extension and the severity of the NLDO (6).

Best outcomes are reported for some favorable conditions such as acquired focal, incomplete obstructions and short distal nasolacrimal duct occlusions (5,19,24,28,29-37 (Table 1).

Indeed, in one of the largest series (31), 350 patients with idiopathic-acquired LDS obstruction were enrolled to evaluate the initial and long-term results of balloon dacryocystoplasty. The lesions were classified according to cause, severity, site of the obstruction, the diameter and inflation time of the balloon. The investigators achieved an overall technical success rate of 95.3% and an overall initial success rate was 57.4%. They also stated that the initial success depended by the severity, the site of the stenosis and the diameter of the balloon, while the long-term patency was influenced by the site of the obstruction and the balloon dilatation time.

Similarly, Konuk et al. (30) employed for 99 cases of idiopathic-acquired LDS obstruction. The mean follow-up period ranged 36–142 months. The investigators experienced a higher long-term overall success rate for partial and distal obstruction (73.3%). They concluded that the long-term success rate of balloon dacryocystoplasty for the treatment of epiphora is disappointing compared to surgery, but positive outcomes can be gained in carefully selected patients with partial obstruction of the distal nasolacrimal duct.

Altogether, these results suggest that balloon dacryocystoplasty cannot ensure the same effectiveness of traditional surgical treatment, but can still be helpful as first line therapy in some selected cases.

**Nasolacrimal stent placement**

Proposed for the first time by Song et al. in 1994 (38), the

<table>
<thead>
<tr>
<th>Study</th>
<th>LDS (n)</th>
<th>PPR (%)</th>
<th>Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Konuk et al. (30)</td>
<td>50*</td>
<td>68*</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td>49b</td>
<td>41b</td>
<td></td>
</tr>
<tr>
<td>Janssen et al. (19)</td>
<td>100</td>
<td>70</td>
<td>48</td>
</tr>
<tr>
<td>Lee et al. (31)</td>
<td>430</td>
<td>48</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>37</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Ilgit et al. (24)</td>
<td>80</td>
<td>66</td>
<td>18</td>
</tr>
<tr>
<td>Ko et al. (32)</td>
<td>195</td>
<td>40</td>
<td>24</td>
</tr>
<tr>
<td>Berkefeld et al. (28)</td>
<td>47a</td>
<td>73a</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>38b</td>
<td>50b</td>
<td></td>
</tr>
</tbody>
</table>
positioning of nasolacrimal plastic stent is a minimally invasive radiological procedure, developed with the aim of overcoming the failures of dacryocystoplasty in treatment of epiphora.

The device introduced by Song is a 6-French polyurethane nasolacrimal stent, equipped with a mushroom proximal tip (5 mm in diameter and length), which can be compressed during the delivery phase and expanded during the deployment. The stent is also 35 mm long, with an outer diameter of 2 mm and luminal diameter of 1.5 mm.

Compared with the expandable metallic stents previously tested by the same Song with deceiving results (39), the polyurethane device revealed higher elasticity and less foreign body inflammatory reaction (38,40).

The stent placement is performed under fluoroscopic guidance in lateral projection and can be preceded by a former dacryocystoplasty (6).

As well as in balloon dacryocystoplasty, an initial DSD is needed to plan the intervention. Then, after crossing the stenosis with a metallic probe, a 6-French sheath with a dilator is advanced retrograde over the guidewire until its tip achieves the lacrimal sac (6,41). This is a crucial moment and the position of the tip must be controlled with injection of contrast medium through the sheath, removing the dilator (41). After this check, the stent can be threaded in the sheath and when its proximal tip gains the lacrimal sac, the sheath can be withdrawn, while the stent pusher is held. The result is the stent deployment and the expansion of its mushroom tip in the lacrimal sac (6,41). Ciampi et al. in 2011 proposed a little variant of this technique, suggesting the delivery of the stent advancing the device over the wire inside a specially designed tapered dacryocystography catheter (42). However, in all cases the procedure must be concluded with a final DSD to verify the position and the patency of the stent (6,41). Furthermore, irrigation of the LDS is required the day after the intervention in order to wash the stent and assure its patency (6).

Like dacryocystoplasty, stent placement is a procedure that can be performed simply under local anesthesia during the day hospital recovery, involving a prophylactic one week therapy with topical corticosteroids and antibiotics (43). However, in this case the risk of complications is mildly increased compared to balloon dilatation, as possible side effects include also foreign body sensation, headache, stent mal-positioning or migration and acute dacryocystitis (40,43).

Interestingly, the only contraindication for nasolacrimal stent placement is acute dacryocystitis, while canalicular obstruction, LDS structural malformations, dacryolithiasis, sac neoplasm or previous sinus surgery, which generally preclude balloon dacryocystoplasty, can be considered as relative exclusion criteria (40).

Table 2 reports several experiences of nasolacrimal stenting (17,40-42,44-49).

The most important limit of this procedure is the occlusion of the stent within one year from the intervention, induced by a chronic low-grade inflammation leading to the growth of granulation tissue inside the mesh of the stent (49). In 2003, 10 years after the invention of nasolacrimal stenting technique, Song published a study (50) aimed to compare the clinical effectiveness of a covered nitinol stent with that of a polyurethane stent for treatment of epiphora in 68 patients. The results were deceiving: even if technical success was achieved in more than 94% of patients, with the immediate resolution of epiphora in all cases, during the mean follow-up period of 40 months, the recurrence of the NLDO was assessed in 30 of 31 patients treated with nitinol stent and 26 of 35 patients who received the plastic one. The authors concluded that despite the polyurethane stent used for treatment seemed to be more effective than the nitinol stent, in both cases the long-term patency rates were not encouraging (50).

Different strategies were suggested in order to overcome this limit.

Lee et al. (51) achieved the highest long-term patency rate in the literature (93.2%) after a mean follow-up of 22 months at 1, 3, and 6 months, performing a periodical irrigation of the LDS through the canaliculi after stent placement with a saline solution containing antibiotics and mucolytics to avoid the inflammatory occlusion of the stent (51).

Moreover, Ciampi et al. in 2011 (42) described an experience, employing in 115 cases of epiphora a new polyurethane stent featured by a special S-shaped configuration to assist placement. The median duration of primary patency was 11 months, while the percentage of patency at 6 months was 60.8%, at 1 year was 39.6%, and at 2 years was 25%. The authors considered these results as a demonstration of the benefit of the stent positioning for NLDO (42).

Eventually in 2017 some investigators (52), proposed in a preclinical study on rabbits the utilization of biodegradable stents containing poly-L-lactic acid-polycaprolactone-polyethylene glycol (PLLA-PCL-PEG) complexes for therapeutic applications in epiphora. The histopathological testing indicated that the selected stent was biodegradable and caused minimal stimulation and earlier tissue
restoration in the lacrimal epithelium, so that the authors concluded that it could represent an interesting alternative choice in treatment of NLDO (52).

However, it should be considered that even when the stent occlusion occurs, this affects, but does not preclude a further surgical intervention (6). Furthermore, stent removal is a well-tolerable procedure, that can be provided either with fluoroscopic, endoscopic or surgical approach (43,53).

**Conclusions**

Interventional radiological procedures represent a minimal invasive option for treatment of epiphora. Despite the long-term success rate is certainly lower than the surgical therapy, these procedures can still constitute a useful treatment option in NLDO, considering their low morbidity rate, their repeatability and the possibility of a further surgical approach in case of failure.

**Acknowledgements**

None.

---

**Table 2** Comparison of results of nasolacrimal polyurethane stents in the treatment of epiphora

<table>
<thead>
<tr>
<th>Study</th>
<th>LDS (n)</th>
<th>TS (%)</th>
<th>F.U. range (months)</th>
<th>F.U. mean (months)</th>
<th>Patency rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Song et al. (40,44,45)</td>
<td>283</td>
<td>95</td>
<td>13–33</td>
<td>23</td>
<td>69</td>
</tr>
<tr>
<td>Pulido-Duque et al. (46)</td>
<td>40</td>
<td>100</td>
<td>1–8</td>
<td>4</td>
<td>88</td>
</tr>
<tr>
<td>Schaudig and Maas (47)</td>
<td>19</td>
<td>95</td>
<td>NA</td>
<td>24</td>
<td>50</td>
</tr>
<tr>
<td>Perena et al. (48)</td>
<td>74</td>
<td>92</td>
<td>NA</td>
<td>15</td>
<td>83</td>
</tr>
<tr>
<td>Lanciego et al. (33)</td>
<td>180</td>
<td>97</td>
<td>1–24</td>
<td>15</td>
<td>86</td>
</tr>
<tr>
<td>Song et al. (34)</td>
<td>609</td>
<td>96</td>
<td>NA</td>
<td>NA</td>
<td>19*</td>
</tr>
<tr>
<td>Paúl et al. (35)</td>
<td>89</td>
<td>89</td>
<td>16–38</td>
<td>27</td>
<td>40</td>
</tr>
<tr>
<td>Yazici et al. (5)</td>
<td>52</td>
<td>96</td>
<td>14–44</td>
<td>23</td>
<td>69</td>
</tr>
<tr>
<td>Kang et al. (36)</td>
<td>727</td>
<td>96</td>
<td>1–65</td>
<td>19</td>
<td>12/5*</td>
</tr>
<tr>
<td>Lanciego et al. (37)</td>
<td>470</td>
<td>95</td>
<td>1–67</td>
<td>24</td>
<td>68/59*</td>
</tr>
<tr>
<td>Oztürk et al. (49)</td>
<td>53</td>
<td>96</td>
<td>18–31</td>
<td>23</td>
<td>31</td>
</tr>
<tr>
<td>Ciampi et al. (42)</td>
<td>104</td>
<td>94</td>
<td>0–28</td>
<td>13</td>
<td>61/40/25*</td>
</tr>
<tr>
<td>Preziosi et al. (41)</td>
<td>73</td>
<td>96</td>
<td>3–60</td>
<td>12</td>
<td>68</td>
</tr>
<tr>
<td>Pinilla et al. (17)</td>
<td>86</td>
<td>88</td>
<td>1–84</td>
<td>24</td>
<td>57</td>
</tr>
</tbody>
</table>

*5-year primary patency rate; 5, 3- and 5-year primary patency rate; 5, 2- and 5-year primary patency rate; 5, 6-month, 1- and 2-year primary patency rate. LDS, lacrimal drainage system; TS, technical success; NA, not available.

---

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

**References**

7. Linberg JV, McCormick SA. Primary acquired
34. Song HY, Lee DH, Ahn H, et al. Intervention in the